

Human-Relevant Non-Animal Methodologies (NAMs)

Specialised Models Series – Metabolic, Digestive & Endocrine

Metabolic Syndrome & Obesity Models

Reference 5.6 in Full Scope Roadmap

Version 1.0 | June 2026 Edition

Compiled for the Alliance for Cruelty Free Science by Georgina Rednall

*Prepared for Academic Leadership, Animal Welfare & Ethical Review Bodies (AWERB), and
Principal Investigators*

Legal & Scientific Imperative for Universities

Section 2A of the Animals (Scientific Procedures) Act 1986 imposes a statutory duty on the Secretary of State to ensure compliance with the principles of replacement, reduction, and refinement. The principle of replacement requires that, wherever a specialised, scientifically satisfactory method or testing strategy not entailing the use of protected animals is available, it must be used to replace the use of a regulated procedure.

Metabolic syndrome is a cluster of conditions—obesity, insulin resistance, and dyslipidaemia—that drive global morbidity. Traditional murine and rodent models (e.g., diet-induced obesity) fail to accurately mirror the human metabolic phenotype. Key disparities include:

- **Metabolic Divergence:** Human and mouse adipose tissue biology differs fundamentally regarding lipid storage, signalling, and inflammatory pathways.
- **Immune-Metabolic Mismatch:** The "metaboinflammation" observed in human obesity is highly complex, involving context-dependent signalling that is poorly recapitulated in standardised murine dietary models.
- **Severity:** Animal models require chronic high-fat/high-sugar feeding protocols that inflict systemic stress, hepatic injury, and chronic discomfort, resulting in significant animal suffering.

Introduction & Regulatory Momentum

5.6 Metabolic Syndrome & Obesity Models | Reference 5.6 in Full Scope Roadmap

This section details human-relevant platforms, including adipose-on-a-chip, liver organoids, and systemic "metabolic-axis" NAMs that model human insulin signalling and lipid metabolism.

Integration Context: Roadmap Cohesion

Metabolic syndrome research (5.6) is the functional confluence of the previous modules. It relies on the endocrine feedback loops (5.4) and the microbiome-driven metabolic flux (5.5) previously mapped. By adopting these integrated NAMs, universities build a cross-disciplinary regulatory framework where Replacement strategies in endocrine and digestive domains reinforce the study of complex metabolic diseases.

Landmark Regulatory & Scientific Momentum

- Adipose-on-a-Chip: Recreates the human adipocyte-macrophage interface, allowing real-time study of chronic low-grade inflammation (metaboinflammation).
- Liver-on-a-Chip: 3D iPSC-derived hepatocytes that model steatosis (fatty liver) and insulin resistance in response to nutrient oversupply.
- Multi-Organ Metabolic Simulators: Integrated microfluidic systems linking adipose, liver, and muscle tissues to study systemic glucose disposal.

Core Specialised Metabolic Disease Models & Enabling Platforms




Figure 1: Adipose-on-a-Chip depicting hypertrophic adipocytes; Liver organoids modelling steatosis; and integrated multi-organ glucose-disposal circuits.

Table 1: Biological & Tissue-Engineered Platforms

Platform	Key Applications	Benefits for Universities & 3Rs
Adipose-on-a-Chip	Metabolic inflammation (metaboinflammation)	Replaces rodent high-fat diet stress protocols
Liver-on-a-Chip	Steatosis & insulin resistance screening	Bypasses long-term animal liver injury studies
Muscle-Organoid	Insulin-stimulated glucose uptake	Eliminates invasive rodent clamp procedures
Metabolic MOC	Systemic glucose disposal modelling	Replaces multi-organ animal perfusion studies

CROSS CUTTING & ENABLING PLATFORMS FOR METABOLIC SYNDROME & OBESITY MODELS

These enabling genomic and computational frameworks provide the predictive pipelines required for systemic metabolic validation.




Figure 2: PBPK models of glucose kinetics; In silico insulin-signalling pathway mapping; and Multi-omics metabolic flux profiling.

Table 2: Genomic & Computational Frameworks

Platform	Key Applications	Benefits for Universities & 3Rs
Metabolic-PBPK	Simulating systemic glucose clearance	Replaces animal glucose tolerance testing
Insulin Signalling AI	Predicting drug-induced insulin resistance	Bypasses complex in vivo metabolic studies
Fluxomics Pipeline	Mapping fatty acid storage kinetics	Regulatory WoE for Replacement

Strategy • Skills & Capacity

Regulatory Software & Strategy Frameworks

Regulatory acceptance of NAMs—referred to as "fit-for-purpose qualification"—is not a one-size-fits-all process. Researchers should utilise the following frameworks to ensure their computational and biological strategies align with the *Animals (Scientific Procedures) Act 1986* and industry best practices:

- **Context of Use (COU) Documentation:** Before deploying models, clearly define the specific scientific question the model is intended to address. This is critical for demonstrating that the NAM is reliable and suitable for its intended regulatory purpose.
- **Technical Characterisation:** Maintain comprehensive Standard Operating Procedures (SOPs) and study plans for both the biological NAM and any software used to analyse its output. This transparency is vital for successful project licence applications.
- **Early Regulatory Engagement:** Leverage institutional or external regulatory support to track "fit-for-purpose" milestones. Early engagement with the Home Office/ASRU is strongly encouraged to test the acceptability of a computational or NAM-based approach before full project submission.
- **Weight-of-Evidence (WoE) Frameworks:** Use integrated digital dashboards to aggregate data from both *in vitro* (NAM) and *in silico* (computational) sources. Building a strong "weight-of-evidence" argument is the most effective way to strengthen Replacement justifications when moving away from traditional animal models.

Skills, Training, and Capacity Building

- **Tissue Engineering:** Mastery of human primary adipocyte and hepatocyte culture.
- **Quantitative Metabolism:** Bridging fluxomics with phenotypic cell-signalling outputs.
- **Regulatory Competency:** Training on presenting human-specific metabolic NAM data to the Home Office.
- **Technological Literacy:** Competency in integrated multi-organ microfluidic circuit management.

Table 3: Skills •Training, and Capacity Building

Capability Domain	Focus Area	Impact on 3Rs/Replacement
Technical	Organoid & Microfluidic Culture	Direct Replacement of animal models
Bioinformatics	Metagenomic/Flux Data Integration	Bypasses in vivo dietary challenge
Regulatory	ASPA 1986 Compliance & AWERB	Facilitates faster ASRU approvals
Computational	PBPK & Metabolic Flux Simulation	Eliminates invasive animal kinetics studies

"Investing in these four pillars is the essential prerequisite for transitioning from 'experimental pilot' to 'institutional SOP' under the ASPA 1986 statutory framework."

Clinical Translation Case Studies

Case Study 1: Liver-on-a-Chip Identifying Human-Specific Hepatotoxicity

A drug candidate targeting obesity showed no hepatic injury in murine trials but induced severe toxicity in human clinical trials. Liver-on-a-chip analysis subsequently demonstrated that human-specific hepatic lipid pathways were disrupted by the compound. This clinical failure highlights the non-predictive nature of rodent metabolic data; the Liver-on-a-chip platform is now the required "fit-for-purpose" Replacement, directly satisfying the ASPA 1986 mandate.

Case Study 2: Adipose-on-a-Chip Replacing "Diet-Induced Obesity" Models

Replacement of chronic "diet-induced obesity" (DIO) models—which involve prolonged animal suffering via extreme diets—with a human adipose-on-a-chip. This platform models insulin resistance by measuring cytokine release in human cells, providing a robust, ethically compliant Replacement that avoids the systemic suffering inherent in murine models, satisfying the ASPA 1986 mandate.

Executive Summary & Compliance Dashboard

Executive Summary

The current reliance on rodent models, particularly mice, in metabolic research is a primary cause of systemic translational failure. These models fail to recapitulate human-specific physiology, leading to non-predictive toxicology data. This roadmap outlines a transition to human-relevant NAMs (organ-on-a-chip, iPSC-organoids), moving toward a research paradigm that is more accurate, ethically sound, and fully aligned with the ASPA 1986 mandate to transition away from regulated animal procedures.

Compliance Dashboard

Focus Area	Primary Animal Model	NAM Replacement Technology	ASPA 1986 Status
Metabolic Syndrome	Murine DIO / High-Fat Models	Adipose/Liver Organoid Systems	High

Maturity Matrix

- Phase 1 (Exploratory):** Audit animal use.
- Phase 2 (Pilot):** Integrate single-organ NAMs into curriculum.
- Phase 3 (Integration):** Multi-organ circuits & fluxomics.
- Phase 4 (Standardisation):** Replace 100% high-severity animal protocols.

Final Compliance Statement

All proposed models satisfy the Section 2A statutory duty of ASPA 1986. By adopting these methodologies, the institution positions itself at the forefront of the global transition toward human-centric, cruelty-free medical science.

Integration Context: Roadmap Conclusion

The modules detailed in this roadmap—from the fundamental barrier integrity models (5.2) and endocrine axes (5.4) to the complex host-microbiome crosstalk explored in this section (5.5)—demonstrate that replacement is not a siloed scientific exercise but an integrated institutional strategy. By mapping these specialised NAM-based microbiome-host systems into a unified regulatory framework, the institution moves decisively toward a standardised, human-centric research paradigm. This systemic integration is the essential prerequisite for fulfilling the ASPA 1986 statutory duty, ensuring all research is scientifically accurate, ethically aligned, and regulatory compliant.